Home Tags Drug Development
Tag: Drug Development
A top Novartis executive says the $225 billion drug giant is planning for a ‘doomsday scenario’ in cancer treatment
Pharma giant Novartis is developing drugs that could prevent cancer before patients get it. One big question: how will we pay for them?
The FDA just approved a drug that targets cancers based on DNA, rather than where the tumor is in your body
The FDA just approved a new cancer treatment in an unconventional way: not by tumor type, but rather by the genetic mutation the drug targets.
"23andMe has created a research platform to enable interested customers to participate in research - to not wait for solutions to appear, but for people to come together and make discoveries happen," 23andMe's CEO wrote. "By working with GSK, we believe we will accelerate the development of breakthroughs."
DNA-testing company 23andMe has signed a $300 million deal with a drug giant. Here’s how to delete your data if that freaks you out.
Genetics-testing companies like Ancestry and 23andMe can — and frequently do — sell your data to drugmakers. A $300 million deal between 23andMe and the pharmaceutical giant GlaxoSmithKline is the latest example. If that has you thinking about how these companies use your data, here's how to delete it.
Prothena said on Monday that its drug to treat AL Amyloidosis failed a key trial, leading the company to discontinue a later-stage study.
There could be a $35 billion market to treat NASH, a ‘silent disease’ millions are living with — and the competition’s startin...
Work's being done to pinpoint how to treat NASH, as well as research that's being used to better understand the genetics of the disease.
The FDA just turned away Alkermes' approval submission for its new drug to treat major depressive disorder.
TwoXar, a startup that uses software to discover new, experimental drugs, just raised $10 million from investors including SoftBank Ventures.
Bank of America Merrill Lynch says that biotech is the best opportunity in the US stock market right now.
Traders were woefully unhedged for Celgene's 20% stock drop following a disastrous earnings report that saw the company miss on sales and cut forward guidance.